<DOC>
	<DOCNO>NCT01828333</DOCNO>
	<brief_summary>The MATIAS study aim demonstrate limit scope implementation study injectable artesunate may progressively roll nationwide Democratic Republic Congo prefer treatment severe malaria .</brief_summary>
	<brief_title>Malaria Treatment With Injectable ArteSunate</brief_title>
	<detailed_description>In 2010 AQUAMAT study demonstrate treatment severe malaria artesunate child reduce case fatality substantially . An overall reduction 22.5 % mortality African child ( &lt; 15 year ) report use injectable artesunate compare injectable quinine treatment severe malaria cause Plasmodium falciparum . These result high quality evidence lead change WHO guideline treatment severe malaria 2011 . The WHO recommend intravenous artesunate treatment choice severe malaria child adult . In early 2012 Programme National de Lutte contre Paludisme ( PNLP ) DRC support relevant ministry department decide follow WHO guideline change policy treatment severe malaria child adult injectable quinine injectable artesunate . However , process complex undertaking , require many operational clinical adaptation . In order support process , need on-site operational information process consequence switch quinine artesunate . The MATIAS study aim demonstrate limit scope implementation study injectable artesunate may progressively roll nationwide Democratic Republic Congo prefer treatment severe malaria .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Quinine</mesh_term>
	<criteria>Patients ( = 2 month old ) admit one study sit treat severe malaria IV quinine first part study patient treat IV/IM artesunate second part study include . Patients need fulfill WHO criteria severe malaria must unable take oral treatment ( WHO , 2010 , WHO , 2011 ) . In addition participant need give informed consent Conditions : Positive rapid diagnostic test ( RDT ) Plasmodium falciparum HRP2 lactate dehydrogenase and/or positive blood slide ( thick smear ) . Patient consider positive one two test positive . In case negative result test , patient enrol study receive care accord usual routine practice hospital/health center question . Definition severe malaria accord WHO ( WHO , 2010 ) : In patient P. falciparum asexual parasitaemia obvious cause symptom , presence one follow clinical laboratory feature classify patient suffer severe malaria : Clinical feature ( hospital health center ) : impaired consciousness unrousable coma prostration , i.e . generalized weakness patient unable walk sit without assistance failure feed multiple convulsion two episode 24 h deep breathing , respiratory distress ( acidotic breathing ) circulatory collapse shock , systolic blood pressure &lt; 70 mm Hg adult &lt; 50 mm Hg child clinical jaundice plus evidence vital organ dysfunction Complementary Laboratory finding ( hospital ) severe anaemia ( Hb &lt; 5g/dl , pack cell volume &lt; 15 % ) hypoglycemia ( blood glucose &lt; 2.2 mmol/l &lt; 40 mg/dl ) metabolic acidosis ( plasma bicarbonate &lt; 15 mmol/l ) serum creatinine &gt; 265 Ã¬mol/l suggest renal impairment Patients know serious adverse reaction quinine artemisinin derivative patient receive adequate antimalarial treatment 24 hour admission include study . Women know suspected pregnancy trimester include study treat quinine infusion accord new national DRC guideline ( Programme Nationale de Lutte contre le Paludisme , 2012 ) . According current routine procedure determination pregnancy do medical anamnesis and/ positive pregnancy test .</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Malaria</keyword>
	<keyword>Severe</keyword>
	<keyword>Artesunate</keyword>
	<keyword>Quinine</keyword>
	<keyword>Democratic Republic Congo</keyword>
</DOC>